Our industry has spent years working to develop the evidentiary best practices to try and ensure that regulators accept evidence from digital endpoints in support of new drug approvals. But, to date, we’ve thought very little about how payers and HTAs may consider data from digital endpoints in reimbursement and pricing decisions.
In this webinar, DiMe and our partners from Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer, and Savvy Co-op introduced a new suite of resources to support evidence generation strategies for the use of data generated by digital endpoints in value and reimbursement discussions for new drugs.
